

James J Harding

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5759886/publications.pdf>

Version: 2024-02-01

99
papers

10,051
citations

87888

38
h-index

38395

95
g-index

102
all docs

102
docs citations

102
times ranked

17151
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 77-90.	10.7	526
2	A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS222-TPS222.	1.6	0
3	Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 437-437.	1.6	2
4	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
5	Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1540-1548.	7.0	21
6	Characterization, management, and risk factors of hyperglycemia during <sc>PI3K</sc> or <sc>AKT</sc> inhibitor treatment. <i>Cancer Medicine</i> , 2022, 11, 1796-1804.	2.8	8
7	Praluzatamab Ravtansine, a CD166-Targeting Antibodyâ€“Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2020-2029.	7.0	18
8	Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments. <i>Cancers</i> , 2022, 14, 1800.	3.7	7
9	Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3135-3135.	1.6	0
10	Targeting <i>HER2 </i>mutationâ€“positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4079-4079.	1.6	11
11	Clinical and genomic characterization of <i>ERBB2</i>-altered gallbladder cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4114-4114.	1.6	2
12	Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4083-4083.	1.6	0
13	Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in patients (pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4110-4110.	1.6	0
14	Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. <i>Investigational New Drugs</i> , 2021, 39, 785-795.	2.6	9
15	A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS350-TPS350.	1.6	15
16	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. <i>Clinical Cancer Research</i> , 2021, 27, 2168-2178.	7.0	67
17	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. <i>Clinical Cancer Research</i> , 2021, 27, 3845-3853.	7.0	25
18	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	2.1	51

#	ARTICLE	IF	CITATIONS
19	Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, 10, 3059-3067.	2.8	19
20	First-in-human phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of oral GNS561, a palmitoyl-protein thioesterase 1 (PPT1) inhibitor, in patients with primary and secondary liver malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, e16175-e16175.	1.6	3
21	Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. <i>Clinical Cancer Research</i> , 2021, 27, 4101-4108.	7.0	24
22	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	12.8	68
23	Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy. <i>Ophthalmology Retina</i> , 2021, 5, 1187-1195.	2.4	5
24	A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4994-5003.	7.0	24
25	Ablative radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1743-1752.	1.4	6
26	Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. <i>Cancer</i> , 2021, 127, 4585-4593.	4.1	7
27	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. <i>Cancer</i> , 2021, 127, 4393-4402.	4.1	24
28	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 1429-1444.	7.3	73
29	First-in-Humans Imaging with ⁸⁹ Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. <i>Journal of Nuclear Medicine</i> , 2020, 61, 512-519.	5.0	170
30	Pharmacokinetic Assessment of ¹⁸ F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 357-366.	5.0	23
31	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 60.	7.1	112
32	Liver and Bile Duct Cancer. , 2020, , 1314-1341.e11.		8
33	Embolization with microspheres alone for hepatocellular carcinoma with portal vein tumor: analysis of outcome and liver function at disease progression. <i>Hpb</i> , 2020, 22, 588-594.	0.3	3
34	NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation. <i>Radiology</i> , 2020, 297, 225-234.	7.3	15
35	Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. <i>Cancer</i> , 2020, 126, 4967-4974.	4.1	6
36	Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. <i>Cancer Medicine</i> , 2020, 9, 7453-7459.	2.8	11

#	ARTICLE	IF	CITATIONS
37	Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2020, 25, e1825-e1836.	3.7	13
38	Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. <i>Oncologist</i> , 2020, 25, e1837-e1845.	3.7	21
39	Characterization of on-target adverse events caused by TRK inhibitor therapy. <i>Annals of Oncology</i> , 2020, 31, 1207-1215.	1.2	39
40	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. <i>Clinical Cancer Research</i> , 2020, 26, 3239-3247.	7.0	135
41	Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. <i>Investigational New Drugs</i> , 2019, 37, 271-281.	2.6	7
42	Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution. <i>Hpb</i> , 2019, 21, 1541-1551.	0.3	16
43	Secondâ€line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. <i>Cancer</i> , 2019, 125, 4426-4434.	4.1	49
44	Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1582.	7.1	91
45	Aspirin Is Associated With Improved Liver Function After Embolization of Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2019, 213, 1-7.	2.2	48
46	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5202-5211.	7.0	26
47	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusionâ€Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079.	9.4	254
48	Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 918-927.	2.3	26
49	Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 937-945.	7.0	22
50	Regional differences in gallbladder cancer pathogenesis: Insights from a multiâ€institutional comparison of tumor mutations. <i>Cancer</i> , 2019, 125, 575-585.	4.1	34
51	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 2116-2126.	7.0	390
52	In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. <i>Journal of Clinical Investigation</i> , 2019, 129, 3435-3447.	8.2	33
53	Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. <i>Annals of Oncology</i> , 2018, 29, 1402-1408.	1.2	151
54	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸ F-(2 <i>S</i>)-4 <i>R</i>)-4-Fluoroglutamine. <i>Radiology</i> , 2018, 287, 667-675.	7.3	80

#	ARTICLE	IF	CITATIONS
55	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	27.8	572
56	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 50-58.	4.9	41
57	Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. <i>Future Oncology</i> , 2018, 14, 2293-2302.	2.4	25
58	Learning All That We Can From MyPathway. <i>Journal of Clinical Oncology</i> , 2018, 36, 2450-2451.	1.6	1
59	Understanding and quantifying the immune microenvironment in hepatocellular carcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 107-107.	3.0	1
60	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , 2018, 8, 1540-1547.	9.4	138
61	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , 2018, 24, 4154-4161.	7.0	348
62	A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 429-440.	2.3	35
63	Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. <i>BMC Cancer</i> , 2018, 18, 693.	2.6	68
64	Patient perspectives on ipilimumab across the melanoma treatment trajectory. <i>Supportive Care in Cancer</i> , 2017, 25, 2155-2167.	2.2	14
65	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
66	Adjuvant Medications That Improve Survival after Locoregional Therapy. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 971-977.e4.	0.5	9
67	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. <i>Investigational New Drugs</i> , 2017, 35, 742-750.	2.6	10
68	A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. <i>Cancer</i> , 2017, 123, 4556-4565.	4.1	61
69	Reply to: "Adjuvant Medications that Improve Survival after Locoregional Therapy". <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1335-1336.	0.5	1
70	Hepatocellular carcinoma in patients with HIV. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 20-25.	3.8	13
71	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017, 23, 6094-6100.	7.0	161
72	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266

#	ARTICLE	IF	CITATIONS
73	<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	3.0	275
74	Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIc melanoma characterized by a BRAFV600E/K mutation. <i>Oncotarget</i> , 2017, 8, 105000-105010.	1.8	10
75	Acute myeloid leukemia masquerading as hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, E31-E35.	1.4	6
76	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 819-827.	1.4	17
77	Advanced Hepatocellular Cancer: the Current State of Future Research. <i>Current Treatment Options in Oncology</i> , 2016, 17, 43.	3.0	50
78	Immunotherapy in hepatocellular carcinoma: Primed to make a difference?. <i>Cancer</i> , 2016, 122, 367-377.	4.1	112
79	Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 192-192.	1.6	69
80	Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 437-437.	1.6	3
81	Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2016, 5, 66-66.	1.2	33
82	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. <i>Oncologist</i> , 2015, 20, 789-797.	3.7	57
83	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. <i>Cancer Discovery</i> , 2014, 4, 538-545.	9.4	73
84	Cutis Verticis Gyrata in Association With Vemurafenib and Whole-Brain Radiotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, e54-e56.	1.6	34
85	Treating advanced hepatocellular carcinoma: How to get out of first gear. <i>Cancer</i> , 2014, 120, 3122-3130.	4.1	33
86	Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?. <i>Hepatobiliary Surgery and Nutrition</i> , 2014, 3, 168-71.	1.5	2
87	From the liver to the foot: a case of systemic embolism and acrometastasis in hepatocellular carcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 103-7.	0.7	2
88	Clinical activity of ipilimumab for metastatic uveal melanoma. <i>Cancer</i> , 2013, 119, 3687-3695.	4.1	171
89	Ipilimumab for Patients With Advanced Mucosal Melanoma. <i>Oncologist</i> , 2013, 18, 726-732.	3.7	140
90	Systemic therapy for hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2013, 2, 37.	1.2	6

#	ARTICLE	IF	CITATIONS
91	Vemurafenib Sensitivity Skin Reaction after Ipilimumab. <i>New England Journal of Medicine</i> , 2012, 366, 866-868.	27.0	82
92	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. <i>New England Journal of Medicine</i> , 2012, 367, 2316-2321.	27.0	222
93	Targeting Immune Checkpoints. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 153-159.	2.0	41
94	Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 153-9.	2.0	25
95	Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels. <i>Molecular Immunology</i> , 2011, 48, 1160-1167.	2.2	26
96	Characteristic Proinflammatory Serum Cytokine Profiles In Patients with B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3595-3595.	1.4	0
97	Human Dendritic Cell Expression of HLA-DO Is Subset Specific and Regulated by Maturation. <i>Journal of Immunology</i> , 2006, 176, 3536-3547.	0.8	49
98	Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. <i>Immunological Reviews</i> , 2005, 207, 242-260.	6.0	145
99	Selective developmental defects of cord blood antigen-presenting cell subsets. <i>Human Immunology</i> , 2004, 65, 1356-1369.	2.4	49